US4053601A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3-substituted-phenyl-6-hydrazine pyridazines
Assignee: Smith Kline & French Laboratories Ltd
•
Filing: 1975-06-03
•
Granted: 1977-10-11
•
Expires: 1995-06-03
Abstract
Abstract The compounds are 3-((3-substituted amino-2-hydroxypropoxy)-phenyl)-6-hydrazino pyridazines which have β-adrenergic blocking and vasodilator activity.
Inventors
- 👤 William John Coates
- 👤 Anthony Maitland Roe
- 👤 Robert Antony Slater
- 👤 Edwin Michael Taylor
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 09:44
CPC Classifications
C; C07; C07D; C07D303/00; C07D303/02; C07D303/12; C07D303/18; C07D303/20; C07D303/22; C07C; C07C205/00; C07C205/49; C07C205/56; C07C59/00; C07C59/40; C07C59/76; C07C59/90; C07C65/00; C07C65/32; C07C65/40; C07D237/00; C07D237/02; C07D237/06; C07D237/10; C07D237/12; C07D237/18; Y; Y02; Y02P; Y02P20/00; Y02P20/50; Y02P20/55
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
78 words
A compound of the Formula: ##STR34## wherein two of the groups R 1 , R 2 and R 3 are hydrogen and the third group is hydrogen, lower akyl, fluoro, chloro, bromo, trifluoromethyl, hydroxy, lower alkoxy, lower alkenyloxy, lower alkoxycarbonyl, cyano, --CONH 2 , --CH 2 CONH 2 , nitro, amino, lower alkanoylamino, lower alkylamino or di(lower alkyl)amino; R 4 is hydrogen or methyl; R 5 is isopropyl, tertiary butyl or phenylethyl; or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
78 words
A compound of the Formula: ##STR34## wherein two of the groups R 1 , R 2 and R 3 are hydrogen and the third group is hydrogen, lower akyl, fluoro, chloro, bromo, trifluoromethyl, hydroxy, lower alkoxy, lower alkenyloxy, lower alkoxycarbonyl, cyano, --CONH 2 , --CH 2 CONH 2 , nitro, amino, lower alkanoylamino, lower alkylamino or di(lower alkyl)amino; R 4 is hydrogen or methyl; R 5 is isopropyl, tertiary butyl or phenylethyl; or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
33 words
A compound according to claim 1 wherein two of the groups R 1 , R 2 and R 3 are hydrogen and the third group is hydrogen, methyl, fluoro, chloro, methoxy or cyano.
Claim 4
Dependent Claim
18 words
A compound according to claim 1 wherein R 1 , R 2 and R 3 are all hydrogen.
Claim 5
Dependent Claim
27 words
A compound according to claim 1 wherein R 3 is hydrogen and either R 1 or R 2 is trifluoromethyl, allyloxy, -CH 2 CONH 2 and acetamido.
Claim 6
Dependent Claim
25 words
A compound according to claim 4 wherein R 3 is hydrogen and either R 1 or R 2 is --CH 2 CONH 2 or acetamido.
Claim 7
Dependent Claim
11 words
A compound according to claim 1 wherein R 4 is hydrogen.
Claim 8
Dependent Claim
14 words
A compound according to claim 1 wherein R 5 is isopropyl or tertiary butyl.
Claim 9
Dependent Claim
16 words
A compound according to claim 1, said compound being 3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
17 words
A compound according to claim 8, said compound being a salt of 3-[2-(3-t-butylamino-2 -hydroxypropoxy)phenyl]-6-hydrazinopyridazine with sulphuric acid.
Claim 11
Dependent Claim
11 words
A compound according to claim 9, said compound being 3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine hemisulphate.
Claim 12
Dependent Claim
16 words
A compound according to claim 1, said compound being 3-[2-(3-t-butylamino-2-hydroxypropoxy)-4-methylphenyl]-6-hydrazinopyridazine or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
16 words
A compound according to claim 1, said compound being 3-[2-(3-t-butylamino-2-hydroxypropoxy)-4-methoxylphenyl]-6-hydrazinopyridazine or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
16 words
A compound according to claim 1, said compound being 3-[2-(3-t-butylamino-2-hydroxypropoxy)-6-fluorophenyl]-6-hydrazinopyridazine or a pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim
16 words
A compound according to claim 1, said compound being 3-[4-acetamido-2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine or a pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
10 words
A compound according to claim 1 in the S-absolute configuration.
Claim 17
Dependent Claim
37 words
A pharmaceutical composition to concomitantly inhibit β-adrenergic receptors and produce vasodilatation comprising in an effective amount to inhibit said receptors and produce vasodilatation a compound of claim 1 in combination with a pharmaceutically acceptable diluent or carrier.
Claim 18
Dependent Claim
36 words
A method of concomitantly inhibiting β-adrenergic receptors and producing vasodilatation which comprises administering a compound of claim 1 internally to an animal in need thereof in an amount sufficient to block said receptors and produce vasodilatation.
Claim 19
Dependent Claim
28 words
A method of treating hypertension which comprises administering a compound of claim 1 internally to an animal in need therof in an amount sufficient to alleviate said condition.
Claim 20
Dependent Claim
29 words
A method of treating angina pectoris which comprises administering a compound of claim 1 internally to an animal in need thereof in an amount sufficient to alleviate said condition.
Claim 21
Dependent Claim
29 words
A method of treating cardiac arrhythmia which comprises administering a compound of claim 1 internally to an animal in need thereof in an amount sufficient to alleviate said condition.
Claim 22
Dependent Claim
14 words
A compound according to claim 2 wherein R 5 is isopropyl or tertiary butyl.
Claim 23
Dependent Claim
11 words
A compound according to claim 21 wherein R 4 is hydrogen.
Claim 24
Dependent Claim
10 words
A compound according to claim 1, said compound being 3-hydrazino-6-[2-(2-hydroxy-3-isopropylaminopropoxy)-phenyl]pyridazine.
Claim 25
Dependent Claim
10 words
A compound according to claim 1, said compound being 3-[2-(3-t-butylamino-2-hydroxypropoxy)-5-fluorophenyl]-6-hydrazinopyridazine.
Claim 26
Dependent Claim
10 words
A compound according to claim 1, said compound being 3-[4-allyloxy-2-(3-t-butylamino-2-hydroxypropoxy)-phenyl]-6-hydrazinopyridazine.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-10-10 | 1981-04-11 | 1981-10-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-10-10 | 1985-04-11 | 1985-10-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-10-10 | 1989-04-11 | 1989-10-11 | $7700.00 | Window Closed / Lapsed |